Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†

In a retrospective analysis of the EMILIA study, the rate of central nervous system (CNS) progression in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer was similar for trastuzumab emtansine (T-DM1) and for capecitabine–lapatinib. In patients with treated, asymptomatic CNS metastases at baseline, T-DM1 was associated with significantly improved overall survival versus capecitabine–lapatinib.

• Publication year

  2014

• Venue

  Annals of Oncology

• Publication date

  2014-10-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdu486PMID 25355722PMCID 4679405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

  2015cited by this paper
• Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

  2015cited by this paper
• Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?

  2015cited by this paper
• CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

  2013cited by this paper
• A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

  2013cited by this paper
• Breast cancer brain metastases responding to primary systemic therapy with T-DM1

  2013cited by this paper
• Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

  2013cited by this paper
• Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

  2013cited by this paper
• Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases.

  2012cited by this paper
• Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)

  2012cited by this paper
• Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012influential reference
• Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era

  2011cited by this paper
• Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

  2011cited by this paper
• Brain metastases as preventive and therapeutic targets

  2011cited by this paper
• Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

  2011cited by this paper
• Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer

  2011cited by this paper
• Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

  2011cited by this paper
• Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer

  2010cited by this paper
• Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

  2010cited by this paper
• Metastatic behavior of breast cancer subtypes.

  2010cited by this paper
• Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

  2009cited by this paper
• Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

  2009cited by this paper
• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

  2009cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Survival in patients with brain metastases from breast cancer

  2008cited by this paper
• The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

  2008cited by this paper
• Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

  2008cited by this paper
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

  2008cited by this paper
• Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial

  2007cited by this paper
• Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

  2006cited by this paper
• Breast cancer metastasis to the central nervous system.

  2005cited by this paper
• Survival after brain metastases from breast cancer in the trastuzumab era.

  2005cited by this paper
• CNS metastases in breast cancer.

  2004cited by this paper
• Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

  2004cited by this paper
• Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.

  2003cited by this paper
• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  2002influential reference
• Annals of Oncology

  1991cited by this paper
• Oncology Department;

  year unknowncited by this paper

• The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis

  2026cites this paper
• Two Decades of Real-World Data Reveals: Vigilance Signals of Drug-Induced Gingival Bleeding

  2026influential citation
• Impact of progression sites and line of therapy on survival outcomes in patients with HER-2 positive metastatic breast cancer treated with T-DM1

  2025cites this paper
• Antibody-Drug Conjugates in breast cancer.

  2025cites this paper
• Antibody–Drug Conjugates and Beyond: Next-Generation Targeted Therapies for Breast Cancer

  2025influential citation
• Impact of Anti-HER2 Therapies on Overall Survival in Patients with HER2-Positive Metastatic Breast Cancer: Focusing on Intracranial Efficacy of Emerging Treatments

  2025cites this paper
• Pyrotinib-assisted whole brain radiotherapy alleviates HER2-positive advanced breast cancer and brain metastases: a prospective study in patients

  2025cites this paper
• Systemic therapy breakthroughs in the management of brain metastases: A new era for HER2-positive breast cancer.

  2025cites this paper
• Precision medicine approaches to CNS metastatic disease.

  2025cites this paper
• Discovery of natural scaffolds as HER2 inhibitors for breast cancer: virtual screening, molecular dynamics, and biological characterization with selectivity profiling

  2025cites this paper
• Advances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIs

  2025cites this paper
• Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study

  2025cites this paper
• Stereotactic radiosurgery versus whole brain radiotherapy in patients of breast cancer with brain metastasis - A retrospective single-institution analysis.

  2025cites this paper
• Drug resistance in breast cancer: Mechanisms and strategies for management.

  2025cites this paper
• [Brain metastases in breast cancer: Diagnosis and management].

  2025cites this paper
• Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

  2025cites this paper
• Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges

  2025cites this paper
• Anti‑HER2‑targeted therapies for the treatment of advanced HER2‑positive breast cancer with brain metastases (Review)

  2025cites this paper
• Antibody-drug conjugates in breast cancer: current evidence and future directions

  2025influential citation
• T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects

  2025cites this paper
• Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients

  2025cites this paper
• Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis

  2025influential citation
• Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions

  2025influential citation
• Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review

  2025cites this paper
• Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma

  2024cites this paper
• Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases

  2024cites this paper
• Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

  2024cites this paper
• Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.

  2024cites this paper
• Prevention of Brain Metastases: A New Frontier

  2024cites this paper
• Interdisziplinäre Therapie von Hirnmetastasen

  2024cites this paper
• Navigating the Complexities of Brain Metastases Management.

  2024cites this paper
• Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?

  2024cites this paper
• Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis

  2024cites this paper
• Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature

  2024cites this paper
• Neurotoxicity-sparing radiotherapy for brain metastases in breast cancer: a narrative review

  2024cites this paper
• Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery.

  2024cites this paper
• Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes

  2024cites this paper
• Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer.

  2024cites this paper
• Current Evidence in the Systemic Treatment of Brain Metastases from Breast Cancer and Future Perspectives on New Drugs, Combinations and Administration Routes: A Narrative Review

  2024cites this paper
• Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review

  2024cites this paper
• Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases

  2024cites this paper
• Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T-DM1) Through Nano-Delivery System in Breast Cancer Therapy.

  2024cites this paper
• The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options

  2024cites this paper
• DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer

  2024cites this paper
• Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study

  2024cites this paper
• Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

  2024cites this paper
• New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?

  2024influential citation
• Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2-positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022.

  2024cites this paper
• Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

  2024cites this paper
• Local control and toxicity after stereotactic radiotherapy in brain metastases patients and the impact of novel systemic treatments.

  2024cites this paper
• The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review

  2024cites this paper
• Distinct uptake and elimination profiles for trastuzumab, human IgG and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.

  2024cites this paper
• Clinical Practice Guidelines for Brain Metastasis From Solid Tumors

  2024cites this paper
• A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases.

  2024cites this paper
• Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis

  2023cites this paper
• Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases

  2023cites this paper
• Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.

  2023cites this paper
• Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors

  2023cites this paper
• Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process

  2023cites this paper
• Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

  2023cites this paper
• Emerging Targeted Therapies for HER2-Positive Breast Cancer

  2023cites this paper
• Recent trends of characteristics and treatments in adults with newly diagnosed brain metastases.

  2023cites this paper
• Systemic treatments for breast cancer brain metastasis

  2023cites this paper
• Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort

  2023cites this paper
• Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

  2023cites this paper
• Errors in Figure 3.

  2023cites this paper
• Tratamiento sistémico para el cáncer de mama HER2 positivo avanzado. Revisión de la evidencia y abordaje terapéutico en el Instituto Nacional de Cancerología - Colombia

  2023cites this paper
• Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study

  2023cites this paper
• Therapeutic strategies for HER2-positive breast cancer with central nervous system involvement: a literature review and future perspectives

  2023cites this paper
• A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting

  2023influential citation
• Efficacy of Pyrotinib With/Without Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.

  2023cites this paper
• Management of Brain Metastases: A Review of Novel Therapies

  2023cites this paper
• New strategies for the treatment of breast cancer with leptomeningeal metastasis

  2023cites this paper
• BRAIN METASTASES AND NEXT-GENERATION ANTICANCER THERAPIES: A SURVIVAL GUIDE FOR CLINICIANS.

  2023cites this paper
• HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

  2023cites this paper
• Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer

  2023cites this paper
• Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer

  2023cites this paper
• Brain metastasis in de novo stage IV breast cancer.

  2023cites this paper
• Advances in the Management of Central Nervous System Metastases from Breast Cancer

  2023cites this paper
• Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

  2023cites this paper
• Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2+ breast cancer brain metastasis.

  2023cites this paper
• Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.

  2023cites this paper
• An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?

  2023cites this paper
• Efficacy and safety of pyrotinib in combination with albumin‑bound paclitaxel for the treatment of HER2‑positive advanced breast cancer: A real‑world study

  2023cites this paper
• Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits

  2023cites this paper
• Predicting survival and prognosis of postoperative breast cancer brain metastasis: a population-based retrospective analysis

  2023influential citation
• Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients.

  2023cites this paper
• Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?

  2023cites this paper
• Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data.

  2023cites this paper
• A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone

  2023cites this paper
• Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis

  2023cites this paper
• Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer.

  2023cites this paper
• Error in Supplement.

  2023cites this paper
• Clinically significant radiation necrosis following trastuzumab-deruxtecan and brain stereotactic radiosurgery: A case series in breast cancer patients

  2023cites this paper
• Therapies beyond Physiological Barriers and Drug Resistance: A Pilot Study and Review of the Literature Investigating If Intrathecal Trastuzumab and New Treatment Options Can Improve Oncologic Outcomes in Leptomeningeal Metastases from HER2-Positive Breast Cancer

  2023cites this paper
• Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases.

  2023cites this paper
• Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer.

  2023cites this paper
• Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases-Reply.

  2023cites this paper
• Intracranial Metastatic Disease: Present Challenges, Future Opportunities

  2022cites this paper
• Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease

  2022cites this paper